The IDMC’s review identified no significant safety concerns and recommended proceeding with enrollment in the second cohort. AMT-162 is an investigational AAVrh10-based gene therapy that ...

Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.

Results of the Planned Interim Analysis and Update on Topline Read-out for the Essential3 Program: The Independent Data Monitoring Committee (IDMC) overseeing the interim analysis of Study 1 of the ...